Physician profile
Tara Wagner
NPI 1750099008
$2,437.79
in general payments reported to CMS, 2019-2025
29 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $351 · 2024: $1,161 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.51 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.84 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $151.51 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.86 | 2023-2025 | Caplyta |
| Alkermes, INC. | $92.35 | 2024-2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $90.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $81.85 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $76.67 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $64.35 | 2025 | |
| Corcept Therapeutics | $63.77 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $60.68 | 2024-2025 | Trintellix |
| Insulet Corporation | $57.66 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.21 | 2024-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $49.27 | 2024-2025 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $47.99 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.16 | 2024-2025 | |
| Lilly USA, LLC | $43.62 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.64 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $33.47 | 2025 | Rexulti |
| Amgen INC. | $32.26 | 2024-2025 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $29.09 | 2024 | Auvelity |
| Mylan Specialty L.P. | $28.64 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $27.60 | 2025 | Airsupra |
| Gilead Sciences, INC. | $26.54 | 2025 | |
| Tandem Diabetes Care, INC. | $25.99 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $15.91 | 2023 | Vaxelis, Gardasil 9, Vaqta |
| Almatica Pharma LLC | $15.60 | 2024 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $13.81 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $13.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.